This session will go through the main features of the call with the main objective of providing answers to any questions or doubts from researchers considering the submission of projects to I2D2.
The purpose of I2D2 program is to accelerate the process whereby new disruptive therapeutic mechanisms reach patients, by using industrial standards to evaluate the mechanisms at the incubation stage for their potential for clinical application. Although the call will remain open, the first evaluation of Expressions of Interest will be made with those submissions received until September 30th, 2017.
►Please confirm attendance at the following link: https://www.eventbrite.com/o/15117691221
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Proceeds to support clinical development of lead first-in-class progra...
